On March 24, 2026, PTC Therapeutics, Inc. announced the appointment of Jessica Chutter to its Board of Directors. Ms. Chutter, a seasoned biotechnology investment banker with over 40 years of experience at Morgan Stanley, fills a vacancy on the Board and will serve as a Class I director until the annual meeting of stockholders in 2026. Her extensive background includes leadership roles in biotechnology investment banking, where she was instrumental in building Morgan Stanley's biotechnology franchise and advising on significant capital raising and strategic transactions totaling approximately $80 billion and $85 billion, respectively. The appointment is expected to enhance PTC's strategic direction as it continues to grow and develop its pipeline of innovative therapies for rare disorders. PTC's Chairman, Michael Schmertzler, expressed confidence in Ms. Chutter's ability to contribute to the company's future growth, while CEO Matthew B. Klein highlighted her previous advisory role with PTC as a valuable asset. Ms. Chutter's compensation will align with the company's outside director compensation policy, which includes an annual retainer and equity grants. This leadership change is anticipated to positively impact PTC's strategic outlook and operational execution, reinforcing investor confidence in the company's direction.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.